

Access to Isoquinolin-2(1*H*)-yl-acetamides and Isoindolin-2-yl-acetamides from a Common MCR Precursor

Xin Li,[§] Qian Wang,[§] Qiang Zheng, Katarzyna Kurpiewska, Justyna Kalinowska-Tluscik, and Alexander Dömling*



Cite This: *J. Org. Chem.* 2022, 87, 14463–14475




Read Online

ACCESS |

Metrics & More

Article Recommendations

Supporting Information



ABSTRACT: We achieved a divergent synthesis of isoquinolin-2(1*H*)-yl-acetamides (16 examples, up to 90% yields) and regioselective isoindolin-2-yl-acetamides (14 examples, up to 93% yields) in moderate to good yields by reacting various substituted ethanones or terminal alkynes with Ugi-4CR intermediates via an ammonia-Ugi-4CR/Copper(I)-catalyzed annulation sequence reaction. The same intermediate thus gives 2D distant but 3D closely related scaffolds, which can be of high interest in exploiting chemistry space on a receptor. The scopes and limitations of these efficient sequence reactions are described, as well as gram-scale synthesis.

INTRODUCTION

Multicomponent reactions (MCRs) and post transformations of MCR products have become progressively popular, which has made them some of the most successful methods leading to the rapid generation of small-molecule library of high structural diversity and molecular complexity.¹ The Ugi reaction, one of the best-known MCRs, with the advantage of atom economy and environmental benefit, could typically afford a linear bis amide backbone.² However, linear bis amides often have issues with stability, solubility, and distribution–metabolism–pharmacokinetic (DMPK) and are not a preferred scaffold in medicinal chemistry.³ Therefore, Ugi-4CR and its post-amide-cyclization reactions are widely used in medicinal chemistry research due to the diversity of scope and ability to improve the metabolic stability of final products.^{4,5} Isoquinolin-2(1*H*)-yl-acetamide and isoindolin-2-yl-acetamide have attracted increasing attention due to their possible diverse biological activities. The isoquinolin-2(1*H*)-yl-acetamide scaffold, for example, was found in P2X7 inhibitors **I**, proteasome inhibitors **II** or TLR agonists **III** (Figure 1A).^{6–8} Likewise, the isoindolin-2-yl-acetamide also appears in the FDA-proved anticancer drug Lenalidomide,⁹ as well as the antimicrobial

compound **IV** or the EGFR inhibitor EAI045 (Figure 1B).^{10–12}

Not surprisingly, new and superior ways to construct the isoquinolin-2(1*H*)-yl-acetamide scaffold or isoindolin-2-yl-acetamide skeleton are in high demand. Yang's group published a Ugi-4CR/Pd-catalyzed intramolecular arylation reaction to efficiently afford the tricyclic isoquinolin-2(1*H*)-yl-acetamides.¹³

Recently, our group reported a two-step synthesis of privileged tetracyclic isoquinolin-2(1*H*)-yl-acetamide scaffold via an ammonia-Ugi-4CR/copper-catalyzed annulation sequence (Scheme 1A).¹⁴ As for the isoindolin-2-yl-acetamides (Scheme 1B), Ibrahim synthesized a series of (1-benzylidene-3-oxoisoindolin-2-yl)-acetamide derivatives from 3-benzaldehyde and the corresponding amino acids.¹⁰ Most recently, Li's group developed an efficient protocol to construct a DNA-

Received: August 10, 2022

Published: October 25, 2022






Figure 1. Representative bioactive molecules with isoquinolin-2(1H)-yl-acetamide scaffold (A) and isoindolin-2-yl-acetamide skeleton (B).

encoded, isoindolin-2-yl-acetamide-based chemical library with potential lenalidomide-like pharmacological properties.¹⁵ However, to date, no article has achieved the fast synthesis of both isoquinolin-2(1H)-yl-acetamide and isoindolin-2-yl-acetamide derivatives from a common Ugi MCR-based precursor.

Based on previous works on copper-catalyzed cyclization reactions¹⁶ and our ongoing experience in MCR chemistry and post-MCR modifications,¹⁷ we hypothesized that two different polycyclic heterocycles could be accessed by a Ugi/Cu-catalyzed annulation sequence reaction between Ugi adducts and different corresponding reagents. Hence, we report herein the synthesis of either isoquinolin-2(1H)-yl-acetamides or isoindolin-2-yl-acetamides in moderate to good yields by adopting Cu(I)-catalyzed C–C coupling/annulation reaction of the C(sp²)-I/Br bond of Ugi-4CR adducts with substituted ethanones or terminal alkynes, respectively (Scheme 1C).

RESULTS AND DISCUSSION

First, we synthesized 11 Ugi adducts in 27–58% yields via Ugi-ammonia-4CR based on our previous work (Scheme 2).^{4,14}


Then, the Ugi adduct **1a** and acetophenone **2a** were selected for the model copper-catalyzed cyclization reaction for the synthesis of isoquinolin-2(1H)-yl-acetamide **3a**. The target compound **3a** could be achieved in 62% yield by reacting **1a** with 1.5 equivolar **2a** in DMSO at 80 °C for 16 h under N₂ in the presence of 10 mol % CuCl and 2 equivalent Cs₂CO₃ (Table 1, entry 1). Further optimization was done by variation of the nature of the Cu catalyst, base, solvent, reaction time and temperature (Table 1). CuCl₂, CuSO₄, and Cu₂O all failed to improve yield, affording **3a** in 41, 42, and 39%, respectively (entries 2–4). Comparable to CuCl, CuBr₂ and CuI could achieve 63 and 61% yield (entries 5 and 6). When replacing CuCl with CuBr, the yield of **3a** slightly increased to 67% (entry 7). K₂CO₃ and Na₂CO₃ failed to give better yield compared to Cs₂CO₃, only trace products were obtained (entries 8 and 9). Further attempts to change the solvent DMSO to MeCN, dioxane, MeOH, toluene, THF and DMF didn't achieve any yield improvements (entries 10–15). To our delight, increasing the temperature from 80 to 90 or 100

°C provided higher yields of 79% and 78%, respectively (entries 16 and 17). Furthermore, decreasing the reaction time significantly reduced the yield (entries 18–20), and likewise, using microwave irradiation to promote the reaction was not advantageous, resulting in a lower yield (33%, entry 21). Therefore, the optimal reaction condition is: Ugi intermediate **1a** (0.3 mmol), acetophenone **2a** (0.45 mmol), 10 mol % CuBr, and 2.0 equiv of Cs₂CO₃ in DMSO (2 mL) at 90 °C for 16 h (entry 16). At the same time, we also screened the reaction condition for the synthesis of isoindolin-2-yl-acetamide **5a** and found the best condition as follows: Ugi intermediate **1a** (0.3 mmol), phenylethyne **4a** (0.45 mmol), 20 mol % CuBr, and 2.0 equiv of K₂CO₃ in PEG (2 mL) at 100 °C for 2 h (Table S2, entry 13).

With optimized conditions in hand, we then investigated the substrate scope and limitations toward the corresponding isoquinolin-2(1H)-yl-acetamides **3a–3p** (Scheme 3) and isoindolin-2-yl-acetamides **5a–5o** (Scheme 4). First, we summarized the scope for the synthesis of isoquinolin-2(1H)-yl-acetamide derivatives. Overall, paraformaldehyde-based Ugi starting materials were tolerated in the domino reactions to efficiently give the desired products (**3a–3p**). Various substituted ethanones performed well with *tert*-butyl isocyanide-derived Ugi adducts in the cyclization reaction to give corresponding products (**3a–3j**) in moderate to good yields (53–90%). Aryl-substituted ethanones (acetophenones) proceeded smoothly to afford the isoquinolin-2(1H)-yl-acetamide derivatives in good yield (**3a–3e**). Among them, acetophenone gave optimal yield (**3a**, 79%), weak electron-withdrawing groups such as 4-Br resulted in slightly lower yield (**3b**, 70%), likewise, double-substituted ethanones like 1-phenyl-2-methyl-ethanone (**3c**, 62%) or 1,2-diphenyl-ethanone (**3e**, 70%) also gave decreased yields. 1-Aceto-naphthone gave 65% yields (**3d**).

When cyclohexanone and cyclopentanone were employed, the desired compounds could be obtained in 75% (**3f**) and 53% (**3g**) yields, comparable to the yields achieved by the above aromatic ethanones. Interestingly, acetone worked very well, providing the target compound (**3h**) in 90% yield. Noteworthy, acetaldehyde was also tolerated in this reaction,

Scheme 1. Strategies of Isoquinolin-2(1H)-yl-acetamide and Isoindolin-2-yl-acetamide




yielding 60% of **3i**. The substituted Ugi intermediate 4-Br-2-iodobenzamide worked also well and resulted in the formation of **3j** (53% yield). When Ugi adducts formed by *tert*-octyl-isocyanide were applied to the annulation reaction, the final products (**3k–3o**) were obtained in moderate to good yields, whereas the cyclohexyl isocyanide-based Ugi substrate provided compound **3p** in 48% yield. We also observed limitations of the reaction (Table S4, **3q** and **3r**). 4-F-acetophenone yielded only trace amounts of product **3q**, possibly due to lower acetyl activity in the structure. In addition, 4-NO₂-2-iodobenzamide even couldn't undergo the reaction, probably because it is difficult to achieve oxidative addition with acetophenone. The structures of **3e** and **3i** were unambiguously elucidated by X-ray.

Then, the scope for constructing the isoindolin-2-yl-acetamides was investigated (Scheme 4). Different terminal alkynes could be successfully employed in the reaction and produce the desired target compounds (**5a–5d**) with excellent regioselectivity (*Z/E* ≥ 94/6), aryl alkynes such as phenyl-

ethyne (**5a**), 4-Br-phenylethyne (**5b**), 2-pyridylethyne (**5c**) gave good yields (81–93%), while alkyl alkyne like trimethylsilylacetylene (**5d**) resulted in 15% yield. 5-Methoxy-2-bromobenzamide and ethyl aldehyde originated Ugi adducts were also tolerated, providing compounds **5e** (*Z/E* = 95/5, 90%) and **5f** (*Z/E* = 88/12, 72%) with good regioselectivity.

Aside from Ugi intermediates based on *tert*-butyl isocyanide, the Ugi adducts generated from other alkyl isocyanides like *tert*-octyl-isocyanide and cyclohexyl isocyanide afforded final products **5g–5m** in moderate to excellent yields.

Gratifyingly, Ugi synthons from two aryl nitriles, phenylethyl isocyanide and 2-methoxyphenyl isocyanide could also result in corresponding isoindolin-2-yl-acetamides (**5n–5o**) in good yield, thus widely broadening the scope of the reaction. It should be noted that when the Ugi product from cyclohexyl isocyanide reacted with 2-pyridineacetylene, we could obtain a product (**5k**, *Z/E* = 51/49) with almost equal amounts of *Z* and *E* forms in 73% yield, which was further purified to give **5l**

Scheme 2. Ugi Adducts in This Work^{a,b,c,d}

^aReaction conditions: carboxylic acid (2 mmol), 25% ammonia solution (2.4 mmol), aldehyde (2 mmol), isocyanide (2 mmol), TFE (2 mL), $60\text{ }^\circ\text{C}$, overnight. ^bYield refers to the purified products. ^cPublished Ugi adducts from our previous articles. ^dNew synthesized Ugi adducts in this work.

($Z/E = 96/4$) and **5m** ($Z/E = 9/91$) with better regioselectivity. The 2D NMR correlations were done to assign the structure of **5a** which was subsequently unambiguously determined by X-ray (Figure S5).


To support the preparative usefulness of our method, gram-scale experiments were carried out for the synthesis of isoquinolin-2(1*H*)-yl-acetamide **3a** and isoindolin-2-yl-acetamide **5a** in moderate yields (Scheme 5A). Two CuBr-promoted cyclization reactions of Ugi-4CR-based 2-iodobenzamide **1a** with acetophenone and phenylethyne were conducted on an 8 mmol scale, producing **3a** (1.14 g) and **5a** (1.74g) in 43% and 64% yield, respectively. To further evaluate the potential of the above-described two scaffolds, we performed the Suzuki coupling late-stage functionalization. **3b** and **5b** were coupled with phenylboronic acid and 4-methoxyphenyl boronic acid separately, giving the corresponding products **6a** and **6b** in good yields via Pd-catalyzed Suzuki reaction (Scheme 5B). We also applied our method to synthesize antibacterial compound **IV** (Scheme 5C); however, instead of obtaining the normal cyclization product **IV** directly, we obtained the carboxylic acid **6c**, which may be due to the similar hydrolysis of the methyl ester occurring in the process as in our previous work.⁴ Then, we reacted **6c** with MeOH and SOCl_2 to realize product **IV** (**6d**, $Z/E = 26/74$) in 53% yield.

The herein-reported two complementary syntheses of two related scaffolds are based on a common Ugi-4CR intermediate. Switching between two related scaffolds is often applied in medicinal chemistry and sometimes called “scaffold hopping”. It is of high importance during lead optimization as the two related scaffolds might bind similarly into the same receptor site but might have different pharmacokinetic/pharmacodynamic (PKPD) parameters. Clearly, the two scaffolds align well in 3D (Figure 2) and are therefore potential bioisosteres.

CONCLUSIONS

In summary, we developed an efficient Ugi-4CR/copper(I) catalytic system for the synthesis of two different bioactive potential scaffolds: isoquinolin-2(1*H*)-yl-acetamide and isoindolin-2-yl-acetamide, with the advantages of atom economy, good yields and absence of ligands. Additionally, product diversity can be achieved not only through the Ugi starting materials aldehydes, isocyanides, and 2-halogeno benzoic acids but also by different substituted ethanones and terminal alkynes. The proposed two different reaction mechanisms were also discussed in the Supporting Information. Having access to two different scaffolds from a common MCR precursor potentially facilitates structure–activity relationship (SAR)

Table 1. Optimization of Reaction Conditions



entry	catalyst (10 mol %)	base	solvent	time (h)	temp (°C)	yield 3a (%)
1	CuCl	Cs ₂ CO ₃	DMSO(dry)	16	80	62 ^a
2	CuCl ₂	Cs ₂ CO ₃	DMSO(dry)	16	80	41 ^b
3	CuSO ₄	Cs ₂ CO ₃	DMSO(dry)	16	80	42 ^b
4	Cu ₂ O	Cs ₂ CO ₃	DMSO(dry)	16	80	39 ^b
5	CuBr ₂	Cs ₂ CO ₃	DMSO(dry)	16	80	63 ^b
6	CuI	Cs ₂ CO ₃	DMSO(dry)	16	80	61 ^b
7	CuBr	Cs ₂ CO ₃	DMSO(dry)	16	80	67 ^b
8	CuBr	K ₂ CO ₃	DMSO(dry)	16	80	trace
9	CuBr	Na ₂ CO ₃	DMSO(dry)	16	80	trace
10	CuBr	Cs ₂ CO ₃	MeCN	16	80	8 ^b
11	CuBr	Cs ₂ CO ₃	dioxane	16	80	49 ^b
12	CuBr	Cs ₂ CO ₃	MeOH	16	80	16 ^b
13	CuBr	Cs ₂ CO ₃	toluene	16	80	trace
14	CuBr	Cs ₂ CO ₃	THF	16	80	trace
15	CuBr	Cs ₂ CO ₃	DMF	16	80	30 ^b
16	CuBr	Cs ₂ CO ₃	DMSO(dry)	16	90	79 ^a
17	CuBr	Cs ₂ CO ₃	DMSO(dry)	16	100	78 ^a
18	CuBr	Cs ₂ CO ₃	DMSO(dry)	4	80	37 ^b
19	CuBr	Cs ₂ CO ₃	DMSO(dry)	8	80	43 ^b
20	CuBr	Cs ₂ CO ₃	DMSO(dry)	12	80	55 ^b
21 ^c	CuBr	Cs ₂ CO ₃	DMSO(dry)	2	80	30 ^b

^aReaction conditions: **1a** (0.3 mmol), **2a** (0.45 mmol), catalyst (10 mmol %), base (0.6 mmol), solvent (2 mL), isolated yields. ^bReaction conditions: **1a** (0.1 mmol), **2a** (0.15 mmol), catalyst (10 mmol %), base (0.2 mmol), solvent (1 mL), HPLC yields. ^cMicrowave.

enormously, while allowing optimization of “druglike” properties through scaffold hopping.

EXPERIMENTAL SECTION

General Information. Nuclear magnetic resonance spectra were recorded on a Bruker Avance 500 spectrometer. Chemical shifts for ¹H NMR were reported relative to TMS (δ 0 ppm) or internal solvent peak (CDCl₃ δ 7.26 ppm, CD₃OD δ 3.31 ppm or D₂O δ 4.79 ppm) and coupling constants were in hertz (Hz). The following abbreviations were used for spin multiplicity: s = singlet, d = doublet, t = triplet, dt = double triplet, ddd = doublet of double doublet, m = multiplet, and br = broad. Chemical shifts for ¹³C NMR reported in ppm relative to the solvent peak (CDCl₃ δ 77.23 ppm, DMSO δ 39.52 ppm, CD₃OD δ 49.00 ppm). Flash chromatography was performed on a Grace Reveleris X2 using Grace Reveleris Silica columns (12 g) and a gradient of petroleum ether/ethyl acetate (0–100%) or dichloromethane/methanol (0–20%) was applied. Thin layer chromatography was performed on Fluka precoated silica gel plates (0.20 mm thick, particle size 25 μ m). All isocyanides were made in-house via the Ugi procedure.¹⁸ Benzoic acids, ethanones (2), terminal alkynes (4), and other reagents were purchased from Sigma Aldrich, ABCR, Acros, Fluorochem, AK Scientific, Combiblocks, or A2B and were used without further purification. Mass spectra were measured on a Waters Investigator Supercritical Fluid Chromatograph with a 3100 MS Detector (ESI) using a solvent system of methanol and CO₂ on a Viridis silica gel column (4.6 \times 250 mm², 5 μ m particle size) and reported as (*m/z*). High-resolution mass spectra (HRMS) were recorded using an LTQ-Orbitrap-XL (Thermo Fisher Scientific; ESI pos. mode) at a resolution of 60000@*m/z*400. Melting points were

obtained on a melting point apparatus and were uncorrected. Yields given refer to chromatographically purified compounds unless otherwise stated. Compounds **1a**, **1d**, **1f**, and **1j** were all prepared following our reported literature^{4,14} (Table S3).

General Experimental Procedure and Characterization.
General Procedure for Ugi-4CR Products. To a stirred solution of the carboxylic acid (2 mmol, 1.0 equiv) in 2,2,2-trifluoroethanol (2 mL) in a 5 mL vial, 0.3 mL of 25% ammonia solution (2.4 mmol, 1.2 equiv) was added. Aldehyde (2 mmol, 1.0 equiv) and isocyanide (2 mmol, 1.0 equiv) were then introduced into the mixture, the vial was capped, and then the reaction mixture was placed in a heated metal block and stirred at 60 °C overnight. After the completion of the reaction, the solvent was removed in vacuo and the crude products were purified by column chromatography to give the desired products **1b**, **1c**, **1e**, and **1g–1i** (Table S3).

General Procedure A. A sealed tube was charged with Ugi adduct **1** (0.2/0.3 mmol, 1.0 equiv), substituted ethanones (0.3/0.45 mmol, 1.5 equiv), Cs₂CO₃ (0.4/0.6 mmol, 2.0 equiv), and the CuBr (0.02/0.03 mmol, 0.1 equiv). DMSO (1/2 mL) was added, and the mixture was stirred under N₂ at 90 °C for 16 h. After the reaction, saturated aqueous NaCl (10 mL) and EtOAc (10 mL) were added successively to the cooled reaction mixture. The organic phase was separated, and the aqueous phase was further extracted with EtOAc (3 \times 10 mL). Then, the combined organic layers were dried over anhydrous Na₂SO₄ and concentrated. The residues were purified by column chromatography on silica gel to afford the compounds **3a–3p**.


General Procedure B. A sealed tube was charged with Ugi adduct **1** (0.2/0.3 mmol, 1.0 equiv), terminal alkynes (0.3/0.45 mmol, 1.5 equiv), K₂CO₃ (0.4/0.6 mmol, 2.0 equiv), and the CuBr (0.04/0.06 mmol, 0.2 equiv). PEG-400 (1/2 mL) was added, and the mixture was stirred under N₂ at 100 °C for 2 h. After the reaction, the solvent was removed in vacuo and the residues were purified by column chromatography on silica gel to afford the compounds **5a–5n**.

Procedure C. Compound **3b** or **5b** (0.15 mmol, 1.0 equiv) and the corresponding phenylboronic acid (0.225 mmol, 1.5 equiv) were placed in a 10 mL tube, and toluene/ethanol (v/v = 5:1) (3 mL) and sat. NaHCO₃ (3 mL) were added. The tube was flushed with N₂ for 10 min, then Pd(dppf)Cl₂ (0.015 mmol, 0.1 equiv) was added, and the tube was sealed. The mixture was allowed to react at 90 °C in an oil bath for 12 h. Then, the reaction mixture was cooled to room temperature and treated with H₂O and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. After the removal of EtOAc, the residues were purified by silica gel column chromatography to afford Suzuki coupling products **6a** and **6b**.

4-Bromo-N-(2-(tert-butylamino)-2-oxoethyl)-2-iodobenzamide (1b). It was synthesized according to the procedure of Ugi-4CR reaction on a 2 mmol scale to afford **1b** (236 mg, 27%) as a white solid. mp: 181–182 °C. *R*_f = 0.59 (50% EtOAc/petroleum ether). ¹H NMR (500 MHz, CDCl₃) δ 8.00 (d, *J* = 1.9 Hz, 1H), 7.48 (dd, *J* = 1.9, 8.2 Hz, 1H), 7.24 (d, *J* = 8.2 Hz, 1H), 7.18 (t, *J* = 5.3 Hz, 1H), 6.46 (s, 1H), 4.02 (d, *J* = 5.0 Hz, 2H), 1.34 (s, 9H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 168.9, 167.5, 142.2, 140.1, 131.4, 129.5, 124.7, 93.3, 51.8, 44.6, 28.9. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₃H₁₇BrIN₂O₂, 438.9518, found, 438.9510.

2-Iodo-N-(2-oxo-2-((2,4,4-trimethylpentan-2-yl)amino)ethyl)-benzamide (1c). It was synthesized according to the procedure of Ugi-4CR reaction on a 2 mmol scale to afford **1c** (285 mg, 38%) as a white solid. mp: 158–160 °C. *R*_f = 0.38 (50% EtOAc/petroleum ether). ¹H NMR (500 MHz, CDCl₃) δ 7.87 (dd, *J* = 1.1, 8.0 Hz, 1H), 7.44–7.32 (m, 2H), 7.11 (td, *J* = 1.9, 7.5 Hz, 1H), 6.81 (t, *J* = 5.1 Hz, 1H), 6.13 (s, 1H), 4.05 (d, *J* = 5.2 Hz, 2H), 1.76 (s, 2H), 1.42 (s, 6H), 1.00 (s, 9H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 169.7, 167.3, 141.3, 140.2, 131.6, 128.5, 128.3, 92.7, 55.9, 51.4, 44.7, 31.8, 31.6, 29.4. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₇H₂₆IN₂O₂, 417.1039, found, 417.1021.

N-(1-(tert-Butylamino)-1-oxopropan-2-yl)-2-iodobenzamide (1e). It was synthesized according to the procedure of Ugi-4CR reaction on a 2 mmol scale to afford **1e** (285 mg, 38%) as a brown oil. *R*_f = 0.29 (50% EtOAc/petroleum ether). ¹H NMR (500 MHz,


Scheme 3. Substrate Scope for the Synthesis of Isoquinolin-2(1*H*)-yl-acetamides^{a,b}

^aReaction conditions: 1 (0.3 mmol), 2 (0.45 mmol), Cs₂CO₃ (0.6 mmol), CuBr (0.03 mmol), DMSO (2 mL), 90 °C, 16 h. ^bYield refers to the purified products through a single step.

CDCl₃) δ 7.93–7.75 (m, 1H), 7.37–7.32 (m, 2H), 7.08 (ddd, *J* = 3.3, 5.8, 7.9 Hz, 1H), 6.69 (d, *J* = 7.7 Hz, 1H), 6.40 (s, 1H), 4.61 (dd, *J* = 6.9, 7.7 Hz, 1H), 1.46 (d, *J* = 6.9 Hz, 3H), 1.35 (s, 9H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.0, 169.1, 141.6, 140.1, 131.4, 128.4, 128.3, 92.6, 51.6, 50.0, 28.9, 18.5. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₄H₂₀IN₂O₂, 375.0570, found, 375.0557.

2-Bromo-*N*-(2-(*tert*-butylamino)-2-oxoethyl)-5-methoxybenzamide (1g). It was synthesized according to the procedure of Ugi-4CR

reaction on a 2 mmol scale to afford 1g (287 mg, 42%) as a white solid. mp: 153–155 °C. *R*_f = 0.30 (50% EtOAc/petroleum ether). ¹H NMR (500 MHz, CDCl₃) δ 7.45 (dd, *J* = 0.9, 8.8 Hz, 1H), 7.23 (t, *J* = 5.1 Hz, 1H), 7.05 (dd, *J* = 1.0, 3.1 Hz, 1H), 6.83 (ddd, *J* = 0.9, 3.2, 8.8 Hz, 1H), 6.55 (s, 1H), 4.08 (d, *J* = 5.2 Hz, 2H), 3.79 (d, *J* = 0.9 Hz, 3H), 1.37 (d, *J* = 1.1 Hz, 9H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 167.8, 167.6, 158.9, 137.7, 134.3, 118.0, 114.6, 109.6, 55.7, 51.7, 44.5,

Scheme 4. Substrate Scope for the Synthesis of Isoindolin-2-yl-acetamides^{a,b,c}

^aReaction conditions: 1 (0.3 mmol), 4 (0.45 mmol), K₂CO₃ (0.6 mmol), CuBr (0.06 mmol), PEG-400 (2 mL), 100 °C, 2 h. ^bYield refers to the purified products through a single step. ^cE/Z was calculated based on ¹H NMR.

28.8. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₄H₂₀BrN₂O₃, 343.0657, found, 343.0645.

2-Iodo-N-(2-oxo-2-(phenethylamino)ethyl)benzamide (1h). It was synthesized according to the procedure of Ugi-4CR reaction on a 2 mmol scale to afford 1h (318 mg, 39%) as a white solid. mp: 167–169 °C. *R*_f = 0.44 (50% EtOAc/petroleum ether). ¹H NMR (500 MHz, CDCl₃) δ 7.87–7.83 (m, 1H), 7.38–7.34 (m, 2H), 7.30–7.26 (m, 2H), 7.23–7.16 (m, 3H), 7.11 (ddd, *J* = 3.1, 6.1, 7.9 Hz, 1H), 6.80 (t, *J* = 5.3 Hz, 1H), 6.63 (t, *J* = 5.9 Hz, 1H), 4.10 (d, *J* = 5.2 Hz, 2H), 3.55 (td, *J* = 5.8, 7.2 Hz, 2H), 2.83 (t, *J* = 7.2 Hz, 2H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 169.7, 168.4, 141.2, 140.1, 138.7, 131.6, 128.9, 128.8, 128.5, 128.3, 126.7, 92.6, 43.8, 40.9, 35.7. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₇H₁₈IN₂O₂, 409.0413, found, 409.0400.


2-Iodo-N-(2-((2-methoxyphenyl)amino)-2-oxoethyl)benzamide (1i). It was synthesized according to the procedure of Ugi-4CR reaction on a 2 mmol scale to afford 1i (238 mg, 29%) as a white solid. 181–183 °C. *R*_f = 0.54 (50% EtOAc/petroleum ether). ¹H NMR (500 MHz, CDCl₃) δ 8.30 (dd, *J* = 1.7, 8.0 Hz, 1H), 8.26 (s,

1H), 7.89 (dd, *J* = 1.1, 8.0 Hz, 1H), 7.47 (dd, *J* = 1.9, 7.6 Hz, 1H), 7.40 (td, *J* = 1.3, 7.6 Hz, 1H), 7.13 (td, *J* = 1.8, 7.6 Hz, 1H), 7.08 (td, *J* = 1.7, 7.9 Hz, 1H), 6.96 (td, *J* = 1.4, 7.9 Hz, 1H), 6.92–6.87 (m, 1H), 6.73 (s, 1H), 4.33 (d, *J* = 5.2 Hz, 2H), 3.89 (s, 3H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 169.6, 166.2, 148.0, 141.3, 140.1, 131.5, 128.5, 128.2, 126.9, 124.4, 121.1, 120.0, 110.1, 92.5, 55.8, 44.5. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₆H₁₆IN₂O₃, 411.0206, found, 411.0190.


Methyl (2-iodobenzoyl)glycylglycinate (1j). It was synthesized according to the procedure of Ugi-4CR reaction on a 2 mmol scale to afford 1j (293 mg, 39%) as a white solid. 100–102 °C. *R*_f = 0.24 (3% MeOH/DCM). ¹H NMR (500 MHz, CDCl₃) δ 7.83 (d, *J* = 8.0 Hz, 1H), 7.39 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.35 (t, *J* = 7.5 Hz, 1H), 7.30 (d, *J* = 6.4 Hz, 1H), 7.15–7.02 (m, 2H), 4.22 (d, *J* = 5.3 Hz, 2H), 4.04 (d, *J* = 5.5 Hz, 2H), 3.71 (s, 3H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 170.1, 169.9, 169.1, 141.2, 140.0, 131.5, 128.5, 128.3, 92.6, 52.5, 43.6. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₂H₁₄IN₂O₄, 376.9998, found, 376.9988.

Scheme 5. Gram-Scale Reaction, Suzuki Coupling Functionalization, and Bioactive Compound Synthesis


A. Gram-scale synthesis:



B. Suzuki Coupling reaction:



C. Synthesis of bioactive compound IV:



N-(*tert*-Butyl)-2-(1-oxo-3-phenylisoquinolin-2(1*H*)-yl)acetamide (**3a**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3a** (79 mg, 79%) as a yellow solid. mp: 203–205 °C. *R*_f = 0.48 (30% EtOAc/petroleum ether). ¹H NMR (500 MHz, CDCl₃) δ 8.42 (d, *J* = 8.0 Hz, 1H), 7.68–7.62 (m, 1H), 7.51–7.43 (m, 7H), 6.48 (s, 1H), 5.92 (s, 1H), 4.43 (s, 2H), 1.31 (s, 9H).

¹³C{¹H} NMR (126 MHz, CDCl₃) δ 167.0, 163.5, 143.9, 136.7, 135.7, 132.8, 129.4, 129.3, 128.7, 128.2, 126.9, 126.1, 124.8, 108.2, 51.5, 50.4, 28.8. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₂₃O₂N₂, 335.1754, found, 335.1746.

2-(3-(4-Bromophenyl)-1-oxisoquinolin-2(1*H*)-yl)-*N*-(*tert*-butyl)-acetamide (**3b**). It was synthesized according to procedure A on a 0.2




Figure 2. Alignment of energy-minimized isoquinolinone **3a** and isoindolinone **5a** supporting the similar 3D shape of the two scaffolds.

mmol scale to yield final compound **3b** (58 mg, 70%) as a white solid. mp: 214–216 °C. $R_f = 0.31$ (25% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.43 (dd, $J = 8.1, 1.3$ Hz, 1H), 7.67 (td, $J = 7.4, 1.5$ Hz, 1H), 7.59 (d, $J = 8.5$ Hz, 2H), 7.54–7.47 (m, 2H), 7.38 (d, $J = 8.4$ Hz, 2H), 6.46 (s, 1H), 5.87 (s, 1H), 4.38 (s, 2H), 1.33 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.9, 163.5, 142.8, 136.6, 134.6, 133.0, 132.0, 131.2, 128.3, 127.2, 126.2, 125.0, 123.9, 108.4, 51.7, 50.6, 28.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{25}\text{O}_2\text{N}_2\text{Br}$, 413.0859, found, 413.0858.

N-(*tert*-Butyl)-2-(4-methyl-1-oxo-3-phenylisoquinolin-2(1H)-yl)-acetamide (**3c**). It was synthesized according to procedure A on a 0.3 mmol scale to yield the final compound **3c** (65 mg, 62%) as a white solid. mp: 178–180 °C. $R_f = 0.29$ (33% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.52 (dt, $J = 8.0, 1.3$ Hz, 1H), 7.77–7.67 (m, 2H), 7.54 (ddd, $J = 8.2, 6.4, 1.9$ Hz, 1H), 7.47 (dd, $J = 5.0, 1.9$ Hz, 3H), 7.32–7.28 (m, 2H), 5.65 (s, 1H), 4.34 (s, 2H), 2.02 (s, 3H), 1.28 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.9, 162.8, 140.0, 137.6, 135.1, 132.8, 130.0, 129.1, 129.0, 128.5, 126.8, 125.2, 123.5, 111.3, 51.5, 50.5, 28.9, 28.8, 15.1. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{25}\text{O}_2\text{N}_2$, 349.1911, found, 349.1910. $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{22}\text{H}_{24}\text{O}_2\text{N}_2\text{Na}$, 371.1731, found, 371.1729.

N-(*tert*-Butyl)-2-(3-(naphthalen-1-yl)-1-oxoisoquinolin-2(1H)-yl)-acetamide (**3d**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3d** (75 mg, 65%) as a white solid. mp: 217–219 °C. $R_f = 0.43$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.51 (d, $J = 8.0$ Hz, 1H), 7.97 (d, $J = 8.1$ Hz, 1H), 7.93 (d, $J = 7.1$ Hz, 1H), 7.69 (t, $J = 7.5$ Hz, 1H), 7.63–7.58 (m, 2H), 7.54 (dd, $J = 13.4, 8.1$ Hz, 4H), 7.46 (t, $J = 6.9$ Hz, 1H), 6.59 (s, 1H), 5.46 (s, 1H), 1.61 (s, 2H), 1.21 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.5, 163.5, 141.5, 136.8, 133.4, 132.9, 132.4, 132.0, 129.9, 128.8, 128.7, 128.4, 127.4, 127.1, 126.6, 126.2, 125.5, 125.1, 109.1, 51.5, 49.6, 28.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{25}\text{O}_2\text{N}_2$, 385.1911, found, 385.1913.

N-(*tert*-Butyl)-2-(1-oxo-3,4-diphenylisoquinolin-2(1H)-yl)-acetamide (**3e**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3e** (86 mg, 70%) as a white solid. mp: 209–211 °C. $R_f = 0.19$ (20% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.53 (dd, $J = 8.0, 1.7$ Hz, 1H), 7.52 (dddd, $J = 27.0, 8.2, 7.1, 1.5$ Hz, 2H), 7.22–7.12 (m, 9H), 7.11–7.05 (m, 2H), 5.73 (s, 1H), 4.43 (s, 2H), 1.30 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.8, 162.9, 141.2, 137.6, 136.5, 134.4, 132.6, 131.6, 130.6, 128.6, 128.2, 128.2, 128.0, 127.0, 126.8, 125.7, 124.9, 119.6, 51.6, 50.4, 28.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{27}\text{O}_2\text{N}_2$, 411.2054, found, 411.2059.

N-(*tert*-Butyl)-2-(6-oxo-2,3,4,6-tetrahydrophenanthridin-5(1H)-yl)acetamide (**3f**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3f** (70 mg, 75%) as a white solid. m.p.: 204–206 °C. $R_f = 0.52$ (20% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.43 (dd, $J = 8.1, 1.7$ Hz, 1H), 7.67 (dd, $J = 6.8, 1.4$ Hz, 1H), 7.62 (dd, $J = 8.3, 1.3$ Hz, 1H), 7.45 (s, 1H), 6.57 (s, 1H), 4.67 (s, 2H), 2.82–2.74 (m, 4H), 1.86 (ddd, $J = 13.2, 4.7, 3.0$

Hz, 4H), 1.30 (s, 9H).; $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 167.8, 163.2, 137.3, 137.2, 132.7, 128.3, 126.2, 124.2, 121.8, 111.8, 51.5, 48.8, 28.8, 27.6, 24.4, 22.8, 22.0. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{25}\text{O}_2\text{N}_2$, 313.1911, found, 313.1911.

N-(*tert*-Butyl)-2-(5-oxo-1,2,3,5-tetrahydro-4H-cyclopenta[*c*]-isoquinolin-4-yl)acetamide (**3g**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3g** (47 mg, 53%) as a white solid. mp: 227–229 °C. $R_f = 0.36$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.39 (d, $J = 8.1$ Hz, 1H), 7.65 (t, $J = 7.5$ Hz, 1H), 7.49–7.36 (m, 2H), 6.53 (s, 1H), 4.57 (s, 2H), 3.14–3.03 (m, 2H), 2.97 (t, $J = 7.4$ Hz, 2H), 2.22 (q, $J = 7.5$ Hz, 2H), 1.30 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 167.2, 163.7, 142.6, 135.5, 132.7, 128.8, 125.8, 124.3, 123.1, 116.0, 51.5, 50.8, 32.6, 29.0, 28.8, 21.5. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{23}\text{O}_2\text{N}_2$, 299.1754, found, 299.1754.

N-(*tert*-Butyl)-2-(3-methyl-1-oxoisoquinolin-2(1H)-yl)acetamide (**3h**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3h** (73 mg, 90%) as a white solid. mp: 176–178 °C. $R_f = 0.3$ (25% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.43–8.19 (m, 1H), 7.61 (td, $J = 7.6, 1.6$ Hz, 1H), 7.46–7.39 (m, 2H), 6.41 (s, 1H), 6.36 (d, $J = 5.4$ Hz, 1H), 4.67 (s, 2H), 2.48 (d, $J = 0.9$ Hz, 3H), 1.31 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 167.4, 163.8, 139.6, 137.1, 132.8, 128.1, 126.3, 125.4, 124.2, 106.7, 51.6, 49.4, 28.8, 20.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{21}\text{O}_2\text{N}_2$, 273.1598; found, 273.1598. $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{20}\text{O}_2\text{N}_2\text{Na}$, 295.1417, found, 295.1414.

N-(*tert*-Butyl)-2-(1-oxoisoquinolin-2(1H)-yl)acetamide (**3i**). It was synthesized according to procedure A on a 0.2 mmol scale to yield final compound **3i** (31 mg, 60%) as a white solid. mp: 202–204 °C. $R_f = 0.12$ (25% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.42 (dd, $J = 8.1, 1.3$ Hz, 1H), 7.66 (ddd, $J = 8.4, 7.1, 1.4$ Hz, 1H), 7.54 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.50 (ddd, $J = 8.2, 7.0, 1.3$ Hz, 1H), 7.17 (d, $J = 7.4$ Hz, 1H), 6.56 (d, $J = 7.3$ Hz, 1H), 6.44 (s, 1H), 4.52 (s, 2H), 1.31 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.9, 162.7, 137.4, 132.7, 132.1, 128.0, 127.2, 126.3, 125.9, 107.0, 54.2, 51.7, 28.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{19}\text{O}_2\text{N}_2$, 259.1441, found, 259.1441.

2-(6-Bromo-1-oxo-3-phenylisoquinolin-2(1H)-yl)-*N*-(*tert*-butyl)-acetamide (**3j**). It was synthesized according to procedure A on a 0.2 mmol scale to yield final compound **3j** (44 mg, 53%) as a white solid. mp: 215–217 °C. $R_f = 0.36$ (20% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.28 (d, $J = 8.6$ Hz, 1H), 7.58 (s, 1H), 7.58 (ddd, $J = 8.6, 2.0, 0.9$ Hz, 1H), 7.48–7.43 (m, 5H), 6.38 (s, 1H), 5.65 (s, 1H), 4.39 (s, 2H), 1.32 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.6, 163.0, 145.3, 138.1, 135.3, 130.14, 130.09, 129.5, 129.3, 128.8, 128.5, 127.9, 123.5, 106.9, 51.7, 50.3, 28.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{O}_2\text{N}_2\text{Br}$, 413.0859, found, 413.0858.

2-(1-Oxo-3-phenylisoquinolin-2(1H)-yl)-*N*-(2,4,4-trimethylpentan-2-yl)acetamide (**3k**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3k** (54 mg, 46%) as a white solid. mp: 203–206 °C. $R_f = 0.26$ (20% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.51–8.32 (m, 1H), 7.64 (ddd, $J = 8.2, 7.1, 1.4$ Hz, 1H), 7.53–7.40 (m, 7H), 6.48 (s, 1H), 6.04 (s, 1H), 4.44 (s, 2H), 1.67 (s, 2H), 1.36 (s, 6H), 0.89 (s, 9H).; $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.6, 163.4, 143.9, 136.6, 135.6, 132.8, 129.5, 129.3, 128.6, 128.1, 126.9, 126.1, 124.8, 108.3, 55.5, 51.8, 50.5, 31.6, 31.5, 29.1. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{31}\text{O}_2\text{N}_2$, 391.2380, found, 391.2377.

2-(1-Oxo-3,4-diphenylisoquinolin-2(1H)-yl)-*N*-(2,4,4-trimethylpentan-2-yl)acetamide (**3l**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3l** (63 mg, 45%) as a white solid. mp: 184–186 °C. $R_f = 0.68$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.53 (dd, $J = 8.0, 1.8$ Hz, 1H), 7.52 (dddd, $J = 25.5, 8.4, 7.1, 1.5$ Hz, 2H), 7.21–7.12 (m, 9H), 7.09–7.06 (m, 2H), 5.80 (s, 1H), 4.42 (s, 2H), 1.66 (s, 2H), 1.36 (s, 6H), 0.90 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.4, 162.8, 141.2, 137.6, 136.5, 134.4, 132.6, 131.6, 130.6, 128.6, 128.2, 128.0, 127.0, 126.9, 125.6, 124.9, 120.0, 55.5, 52.0, 50.6, 31.7, 31.5, 29.1. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{35}\text{O}_2\text{N}_2$, 467.2693, found, 467.2689.

2-(3-(Naphthalen-1-yl)-1-oxoisquinolin-2(1H)-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide (**3m**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3m** (86 mg, 65%) as a white solid. mp: 218–220 °C. $R_f = 0.63$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.55–8.39 (m, 1H), 7.95 (dd, $J = 20.3, 7.7$ Hz, 2H), 7.69 (d, $J = 1.6$ Hz, 1H), 7.62–7.57 (m, 2H), 7.57–7.49 (m, 4H), 7.46 (s, 1H), 6.60 (s, 1H), 5.62 (s, 1H), 4.80 (d, $J = 15.3$ Hz, 1H), 3.76 (d, $J = 15.6$ Hz, 1H), 1.62 (s, 2H), 1.27 (d, $J = 3.0$ Hz, 6H), 0.83 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.1, 163.4, 141.6, 136.8, 133.5, 132.9, 132.4, 132.0, 130.0, 128.8, 128.7, 128.3, 127.4, 127.1, 126.6, 126.2, 125.5, 125.2, 125.0, 109.1, 55.4, 51.9, 49.8, 31.6, 31.4, 29.0 (d, $J = 6.0$ Hz). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{33}\text{O}_2\text{N}_2$, 441.2537, found, 441.2534.

2-(5-Oxo-1,2,3,5-tetrahydro-4H-cyclopenta[*c*]isoquinolin-4-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide (**3n**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3n** (54 mg, 51%) as a white solid. mp: 164–166 °C. $R_f = 0.22$ (20% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.40 (dd, $J = 8.1, 1.7$ Hz, 1H), 7.72–7.60 (m, 1H), 7.50–7.39 (m, 2H), 6.57 (s, 1H), 4.58 (s, 2H), 3.11 (t, $J = 7.9$ Hz, 1H), 2.99 (t, $J = 7.4$ Hz, 1H), 2.22 (p, $J = 7.4$ Hz, 2H), 1.66 (s, 2H), 1.36 (s, 6H), 0.85 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.9, 163.8, 142.5, 135.5, 132.8, 128.8, 125.9, 124.4, 123.2, 116.2, 77.4, 77.2, 76.9, 55.4, 51.7, 51.3, 32.6, 31.6, 31.3, 29.2, 29.1, 21.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{31}\text{O}_2\text{N}_2$, 355.2380, found, 355.2377.

2-(3-Methyl-1-oxoisquinolin-2(1H)-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide (**3o**). It was synthesized according to procedure A on a 0.2 mmol scale to yield final compound **3o** (47 mg, 72%) as a yellow oil. mp: 145–147 °C. $R_f = 0.68$ (5% Acetone/DCM). ^1H NMR (500 MHz, CDCl_3) δ 8.35 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.62 (ddd, $J = 8.2, 7.1, 1.3$ Hz, 1H), 7.45–7.40 (m, 2H), 6.56 (s, 1H), 6.41 (s, 1H), 4.67 (s, 2H), 2.50 (d, $J = 0.9$ Hz, 3H), 1.66 (s, 2H), 1.36 (s, 6H), 0.84 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 167.0, 163.8, 139.5, 136.9, 132.8, 128.1, 126.3, 125.4, 124.1, 106.8, 55.4, 51.7, 49.8, 31.6, 31.3, 29.2, 21.0. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{29}\text{O}_2\text{N}_2$, 329.2224, found, 329.2220.

N-Cyclohexyl-2-(1-oxo-3,4-diphenylisoquinolin-2(1H)-yl)-acetamide (**3p**). It was synthesized according to procedure A on a 0.3 mmol scale to yield final compound **3p** (63 mg, 48%) as a white solid. mp: 149–151 °C. $R_f = 0.28$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.54 (dd, $J = 8.0, 1.8$ Hz, 1H), 7.54 (ddd, $J = 19.5, 8.0, 1.4$ Hz, 2H), 7.23–7.13 (m, 9H), 7.09–7.06 (m, 2H), 5.80 (d, $J = 7.7$ Hz, 1H), 4.45 (s, 2H), 3.73 (dddd, $J = 14.7, 11.8, 8.0, 4.0$ Hz, 1H), 1.91–1.88 (m, 1H), 1.67–1.61 (m, 3H), 1.32–1.28 (m, 2H), 1.15–1.09 (m, 3H), 0.88–0.85 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 166.9, 162.9, 141.2, 137.6, 136.5, 134.3, 132.7, 131.6, 130.6, 128.7, 128.24, 128.18, 128.1, 127.03, 126.95, 125.7, 124.9, 119.7, 50.3, 48.6, 33.1, 25.6, 24.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{29}\text{O}_2\text{N}_2$, 437.2224, found, 437.2222.

(Z)-2-(1-Benzylidene-3-oxoisindolin-2-yl)-N-(tert-butyl)-acetamide (**5a**). It was synthesized according to procedure B on a 0.3 mmol scale to yield final compound **5a** (93 mg, 93%) as a white solid. mp: 174–176 °C. $R_f = 0.40$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.86 (s, 1H), 7.76 (d, $J = 7.7$ Hz, 1H), 7.61 (td, $J = 1.4, 7.6$ Hz, 1H), 7.50 (t, $J = 7.5$ Hz, 1H), 7.39–7.31 (m, 5H), 6.81 (s, 1H), 5.05 (s, 1H), 4.16 (s, 2H), 1.22 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.3, 166.0, 138.5, 135.1, 134.4, 132.4, 129.7, 129.2, 128.5, 127.82, 127.78, 123.7, 119.7, 107.1, 51.4, 46.2, 28.8, 28.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{23}\text{O}_2\text{N}_2$, 335.1754, found, 335.1744.

(Z)-2-(1-(4-Bromobenzylidene)-3-oxoisindolin-2-yl)-N-(tert-butyl)acetamide (**5b**). It was synthesized according to procedure B on a 0.2 mmol scale to yield final compound **5b** (67 mg, 81%) as a white solid. mp: 184–186 °C. $R_f = 0.25$ (20% EA/PE). ^1H NMR (500 MHz, CDCl_3) δ 7.86 (d, $J = 7.6$ Hz, 1H), 7.74 (d, $J = 7.7$ Hz, 1H), 7.61 (t, $J = 7.5$ Hz, 1H), 7.53–7.47 (m, 3H), 7.22 (d, $J = 8.0$ Hz, 2H), 6.68 (s, 1H), 5.11 (s, 1H), 4.16 (s, 2H), 1.24 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.3, 165.8, 138.4, 135.7, 133.4, 132.6, 131.7, 131.4, 129.5, 127.8, 123.8, 121.9, 119.8, 105.5, 51.6, 46.2, 28.7.

HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{O}_2\text{N}_2\text{Br}$, 413.0859, found, 413.0857.

(Z)-N-(tert-Butyl)-2-(1-oxo-3-(pyridin-2-ylmethylene)isoindolin-2-yl)acetamide (**5c**). It was synthesized according to procedure B on a 0.2 mmol scale to yield final compound **5c** (56 mg, 83%) as a white solid. mp: 212–214 °C. $R_f = 0.26$ (50% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.64–8.61 (m, 1H), 7.88 (d, $J = 7.6$ Hz, 1H), 7.79 (d, $J = 6.9$ Hz, 1H), 7.68 (td, $J = 1.9, 7.7$ Hz, 1H), 7.63 (t, $J = 7.6$ Hz, 1H), 7.55–7.50 (m, 1H), 7.40 (d, $J = 7.7$ Hz, 1H), 7.17 (dd, $J = 4.9, 7.6$ Hz, 1H), 6.69 (s, 1H), 5.31 (s, 1H), 4.78 (s, 2H), 1.17 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.3, 167.2, 153.5, 149.3, 139.0, 137.0, 136.6, 132.6, 129.7, 127.8, 125.6, 123.9, 121.9, 119.8, 106.1, 51.2, 47.8, 28.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{22}\text{O}_2\text{N}_3$, 336.1707, found, 336.1708.

(Z)-N-(tert-Butyl)-2-(1-oxo-3-((trimethylsilyl)methylene)isoindolin-2-yl)acetamide (**5d**). It was synthesized according to procedure B on a 0.3 mmol scale to yield final compound **5d** (15 mg, 15%) as a yellow oil. $R_f = 0.28$ (EA/PE/DCM = 1:2:1). ^1H NMR (500 MHz, CDCl_3) δ 8.35 (t, $J = 5.1$ Hz, 1H), 8.08–8.00 (m, 1H), 7.59–7.51 (m, 1H), 7.47–7.37 (m, 2H), 6.14 (s, 1H), 4.09 (d, $J = 5.2$ Hz, 2H), 1.36 (s, 9H), 0.28 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 167.6, 166.4, 135.0, 134.1, 130.9, 130.2, 129.1, 120.0, 103.0, 102.7, 51.6, 44.9, 28.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{25}\text{ON}_3\text{Si}$, 331.1823, found, 331.1823.

(Z)-2-(1-Benzylidene-3-methoxy-3-oxoisindolin-2-yl)-N-(tert-butyl)acetamide (**5e**). It was synthesized according to procedure B on a 0.3 mmol scale to yield final compound **5e** (98 mg, 90%) as a white solid. mp: 174–176 °C. $R_f = 0.58$ (50% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.65 (d, $J = 8.4$ Hz, 1H), 7.39–7.34 (m, 2H), 7.34–7.30 (m, 4H), 7.17 (dd, $J = 2.4, 8.5$ Hz, 1H), 6.69 (s, 1H), 5.00 (s, 1H), 4.15 (s, 2H), 3.89 (s, 3H), 1.23 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.3, 166.1, 161.1, 135.0, 134.6, 131.3, 129.7, 129.3, 128.5, 127.7, 121.2, 121.1, 106.1, 105.9, 55.9, 51.5, 46.4, 28.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{25}\text{O}_3\text{N}_2$, 365.1784, found, 365.1781.

(Z)-2-(1-Benzylidene-3-oxoisindolin-2-yl)-N-(tert-butyl)-propenamide (**5f**). It was synthesized according to procedure B on a 0.3 mmol scale to yield final compound **5f** (75 mg, 72%) as a white solid. mp: 166–168 °C. $R_f = 0.56$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.86 (d, $J = 7.6$ Hz, 1H), 7.77 (d, $J = 7.7$ Hz, 1H), 7.64 (t, $J = 7.6$ Hz, 1H), 7.52 (t, $J = 7.5$ Hz, 1H), 7.38–7.31 (m, 5H), 6.82 (s, 1H), 6.27 (s, 1H), 4.34 (q, $J = 7.2$ Hz, 1H), 1.45 (d, $J = 7.1$ Hz, 3H), 1.36 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.9, 169.6, 139.1, 135.4, 134.0, 132.6, 129.38, 129.36, 128.8, 128.2, 123.4, 119.6, 113.8, 107.7, 55.9, 51.3, 28.8, 15.0. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{25}\text{O}_2\text{N}_2$, 349.1911, found, 349.1909.

(Z)-2-(1-Benzylidene-3-oxoisindolin-2-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide (**5g**). It was synthesized according to procedure B on a 0.2 mmol scale to yield final compound **5g** (69 mg, 88%) as a white oil. $R_f = 0.15$ (1% MeOH/DCM). ^1H NMR (500 MHz, CDCl_3) δ 7.88 (d, $J = 7.6$ Hz, 1H), 7.77 (d, $J = 7.9$ Hz, 1H), 7.62 (t, $J = 6.9$ Hz, 1H), 7.51 (t, $J = 7.5$ Hz, 1H), 7.40–7.32 (m, 5H), 6.82 (s, 1H), 5.18 (s, 1H), 4.16 (s, 2H), 1.57 (s, 2H), 1.31 (s, 6H), 0.89 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.3, 165.8, 138.5, 135.0, 134.2, 132.5, 129.7, 129.3, 128.6, 127.9, 127.8, 123.7, 119.7, 107.3, 55.5, 52.4, 46.5, 31.6, 31.5, 28.7. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{31}\text{O}_2\text{N}_2$, 391.2380, found, 391.2382.

(Z)-2-(1-Benzylidene-3-oxoisindolin-2-yl)-N-cyclohexylacetamide (**5h**). It was synthesized according to procedure B on a 0.2 mmol scale to yield final compound **5h** (54 mg, 75%) as a white solid. mp: 206–208 °C. $R_f = 0.15$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.89 (d, $J = 7.6$ Hz, 1H), 7.78 (d, $J = 7.9$ Hz, 1H), 7.65 (td, $J = 1.3, 7.6$ Hz, 1H), 7.53 (td, $J = 0.9, 7.4$ Hz, 1H), 7.39–7.30 (m, 5H), 6.84 (s, 1H), 5.23 (d, $J = 8.4$ Hz, 1H), 4.20 (s, 2H), 3.64 (dtd, $J = 4.0, 6.9, 10.9$ Hz, 1H), 1.83 (dt, $J = 4.2, 12.1$ Hz, 2H), 1.69–1.63 (m, 2H), 1.57 (dt, $J = 3.9, 12.9$ Hz, 1H), 1.36–1.24 (m, 3H), 1.13–1.03 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.4, 166.1, 138.5, 135.0, 134.1, 132.6, 129.5, 129.4, 128.6, 128.0, 127.8, 123.8, 119.7, 107.5, 48.5, 46.1, 33.0, 25.6, 24.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{25}\text{O}_2\text{N}_2$, 361.1911, found, 361.1911.

(Z)-N-Cyclohexyl-2-(1-(4-methylbenzylidene)-3-oxoisindolin-2-yl)acetamide (**5i**). It was synthesized according to procedure B on a 0.2 mmol scale to yield final compound **5i** (102 mg, 91%) as a white solid. mp: 213–215 °C. $R_f = 0.74$ (50% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.88 (d, $J = 7.6$ Hz, 1H), 7.77 (d, $J = 7.7$ Hz, 1H), 7.64 (td, $J = 1.3, 7.6$ Hz, 1H), 7.52 (td, $J = 1.0, 7.5$ Hz, 1H), 7.22–7.15 (m, 4H), 6.81 (s, 1H), 5.31 (d, $J = 10.6$ Hz, 1H), 4.22 (s, 2H), 3.72–3.62 (m, 1H), 2.37 (s, 3H), 1.84 (dd, $J = 4.0, 12.5$ Hz, 2H), 1.67 (t, $J = 3.9$ Hz, 1H), 1.58 (dt, $J = 3.9, 13.1$ Hz, 1H), 1.37–1.23 (m, 3H), 1.15–0.99 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.5, 166.3, 138.6, 137.9, 134.6, 132.6, 131.0, 129.4, 129.34, 129.26, 127.7, 123.7, 119.7, 107.8, 48.4, 46.2, 33.0, 25.6, 24.9, 21.5. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{27}\text{O}_2\text{N}_2$, 375.2067, found, 375.2063.

(Z)-2-(1-(4-Bromobenzylidene)-3-oxoisindolin-2-yl)-N-cyclohexylacetamide (**5j**). It was synthesized according to procedure B on a 0.2 mmol scale to yield final compound **5j** (110 mg, 84%) as a white solid. mp: 214–216 °C. $R_f = 0.52$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.88 (dt, $J = 1.0, 7.6$ Hz, 1H), 7.77–7.74 (m, 1H), 7.64 (td, $J = 1.3, 7.6$ Hz, 1H), 7.53 (td, $J = 1.0, 7.5$ Hz, 1H), 7.49 (d, $J = 8.4$ Hz, 2H), 7.22–7.19 (m, 2H), 6.70 (s, 1H), 5.28 (d, $J = 8.2$ Hz, 1H), 4.19 (s, 2H), 3.65 (tdt, $J = 4.0, 7.9, 10.9$ Hz, 1H), 1.84 (dt, $J = 3.9, 12.3$ Hz, 2H), 1.66 (dt, $J = 3.9, 14.2$ Hz, 2H), 1.58 (dt, $J = 3.8, 12.9$ Hz, 1H), 1.31 (ddt, $J = 4.2, 13.2, 14.8$ Hz, 2H), 1.15–1.00 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.4, 165.9, 138.4, 135.6, 133.2, 132.7, 131.7, 131.2, 129.6, 127.7, 123.8, 122.1, 119.7, 105.9, 48.6, 46.0, 33.0, 25.6, 24.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{24}\text{O}_2\text{N}_2\text{Br}$, 439.1016, found, 439.1014.

N-Cyclohexyl-2-(1-oxo-3-(pyridin-2-ylmethylene)isoindolin-2-yl)acetamide ($Z:E=51:49$) (**5k**). It was synthesized according to procedure B on a 0.3 mmol scale to yield final compound **5k** (79 mg, 73%) as a white solid. mp: 224–224 °C. $R_f = 0.24$ (50% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.60 (d, $J = 5.5$ Hz, 1H), 7.91–7.85 (m, 1H), 7.80 (d, $J = 7.7$ Hz, 1H), 7.70–7.60 (m, 2H), 7.54 (t, $J = 7.5$ Hz, 1H), 7.39 (d, $J = 7.8$ Hz, 1H), 7.26–7.23 (m, 1H), 7.16 (dd, $J = 7.7, 4.7$ Hz, 1H), 6.69 (s, 1H), 5.53 (d, $J = 8.4$ Hz, 1H), 4.77 (s, 2H), 3.66 (tdt, $J = 11.3, 7.7, 3.9$ Hz, 1H), 1.65–1.52 (m, 5H), 1.34–1.26 (m, 2H), 1.11–0.92 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.4, 167.4, 153.2, 149.3, 139.0, 136.8, 136.6, 132.7, 129.8, 127.7, 125.5, 123.9, 122.0, 119.8, 106.4, 48.2, 47.8, 33.0, 25.6, 24.9. ^1H NMR (500 MHz, CDCl_3) δ 8.73 (d, $J = 5.0$ Hz, 1H), 8.57–8.52 (m, 1H), 7.95–7.85 (m, 2H), 7.74 (td, $J = 7.7, 2.0$ Hz, 1H), 7.57–7.51 (m, 2H), 7.39 (d, $J = 8.0$ Hz, 1H), 6.53 (s, 1H), 5.88 (d, $J = 8.5$ Hz, 1H), 4.55 (s, 2H), 3.78 (tdt, $J = 11.8, 8.0, 4.0$ Hz, 1H), 1.85–1.74 (m, 2H), 1.65–1.52 (m, 3H), 1.34–1.26 (m, 2H), 1.11–0.92 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 167.2, 166.6, 154.0, 149.4, 138.4, 136.8, 135.0, 132.9, 130.3, 129.8, 126.2, 125.9, 123.5, 122.5, 111.7, 48.6, 44.6, 33.0, 25.4, 24.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{24}\text{O}_2\text{N}_3$, 362.1863, found, 362.1862.

(Z)-N-Cyclohexyl-2-(1-oxo-3-(pyridin-2-ylmethylene)isoindolin-2-yl)acetamide (**5l**). It was purified from **5k** on a 0.2 mmol scale to yield final compound **5l** (24 mg, 33%) as a white solid. mp: 232–234 °C. $R_f = 0.40$ (25% EtOAc/DCM). ^1H NMR (500 MHz, CDCl_3) δ 8.60 (d, $J = 3.7$ Hz, 1H), 7.89 (d, $J = 7.6$ Hz, 1H), 7.80 (d, $J = 7.7$ Hz, 1H), 7.70–7.61 (m, 2H), 7.54 (t, $J = 7.5$ Hz, 1H), 7.38 (d, $J = 7.8$ Hz, 1H), 7.16 (dd, $J = 7.6, 4.9$ Hz, 1H), 6.69 (s, 1H), 5.52 (d, $J = 8.2$ Hz, 1H), 4.78 (s, 2H), 3.66 (tdt, $J = 11.3, 8.1, 4.0$ Hz, 1H), 1.76 (d, $J = 4.1$ Hz, 2H), 1.64–1.49 (m, 3H), 1.33–1.20 (m, 2H), 1.06 (tt, $J = 12.4, 3.5$ Hz, 1H), 1.02–0.91 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.4, 167.4, 153.2, 149.4, 139.0, 136.9, 136.6, 132.7, 129.8, 127.7, 125.5, 123.9, 122.0, 119.8, 106.4, 48.2, 47.8, 33.0, 25.6, 24.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{24}\text{O}_2\text{N}_3$, 362.1863, found, 362.1862.

(E)-N-Cyclohexyl-2-(1-oxo-3-(pyridin-2-ylmethylene)isoindolin-2-yl)acetamide (**5m**). It was purified from **5k** on a 0.2 mmol scale to yield final compound **5m** (22 mg, 30%) as a white solid. mp: 228–230 °C. $R_f = 0.29$ (25% EtOAc/DCM). ^1H NMR (500 MHz, CDCl_3) δ 8.74 (d, $J = 3.9$ Hz, 1H), 8.58 (dd, $J = 6.2, 1.5$ Hz, 1H), 7.95–7.85 (m, 1H), 7.75 (td, $J = 7.7, 1.9$ Hz, 1H), 7.61–7.50 (m, 2H), 7.41 (d, $J = 8.0$ Hz, 1H), 6.54 (s, 1H), 5.82 (d, $J = 8.0$ Hz, 1H), 5.30 (s, 1H),

4.56 (s, 2H), 3.78 (tdt, $J = 10.7, 8.1, 4.1$ Hz, 1H), 1.86 (dd, $J = 12.5, 3.5$ Hz, 2H), 1.69–1.61 (m, 2H), 1.55 (d, $J = 3.9$ Hz, 1H), 1.35–1.26 (m, 2H), 1.14–1.01 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 167.2, 166.7, 154.0, 149.5, 138.4, 136.9, 135.0, 132.9, 130.4, 129.7, 126.2, 125.9, 123.6, 122.5, 111.7, 48.7, 44.7, 33.0, 25.5, 24.9. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{24}\text{O}_2\text{N}_3$, 362.1863, found, 362.1862.

(Z)-2-(1-Benzylidene-3-oxoisindolin-2-yl)-N-phenethylacetamide (**5n**). It was synthesized according to procedure B on a 0.2 mmol scale to yield final compound **5n** (61 mg, 80%) as a white solid. mp: 180–182 °C. $R_f = 0.76$ (20% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.88 (d, $J = 7.6$ Hz, 1H), 7.76 (d, $J = 7.7$ Hz, 1H), 7.65 (td, $J = 1.4, 7.6$ Hz, 1H), 7.53 (td, $J = 0.8, 7.6$ Hz, 1H), 7.36–7.28 (m, 3H), 7.24–7.14 (m, 5H), 7.08 (d, $J = 6.5$ Hz, 2H), 6.80 (s, 1H), 5.41 (t, $J = 5.8$ Hz, 1H), 4.21 (s, 2H), 3.36–3.30 (m, 2H), 2.70 (t, $J = 7.1$ Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.0, 167.0, 138.7, 138.3, 134.8, 134.0, 132.6, 129.5, 129.4, 128.8, 128.7, 128.5, 128.0, 127.7, 126.6, 123.7, 119.7, 107.5, 45.7, 40.8, 35.5. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{23}\text{O}_2\text{N}_2$, 383.1754, found, 383.1755.

(Z)-2-(1-(4-Bromobenzylidene)-3-oxoisindolin-2-yl)-N-(2-methoxyphenyl)acetamide (**5o**). It was synthesized according to procedure B on a 0.3 mmol scale to yield final compound **5o** (123 mg, 89%) as a white solid. mp: 185–186 °C. $R_f = 0.50$ (30% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.21 (d, $J = 8.0$ Hz, 1H), 7.92 (d, $J = 7.6$ Hz, 1H), 7.78 (d, $J = 7.7$ Hz, 1H), 7.65 (t, $J = 7.6$ Hz, 1H), 7.55 (t, $J = 7.5$ Hz, 1H), 7.45 (s, 1H), 7.37 (d, $J = 8.2$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 7.03 (t, $J = 7.8$ Hz, 1H), 6.91 (t, $J = 7.8$ Hz, 1H), 6.84 (d, $J = 8.2$ Hz, 1H), 6.73 (s, 1H), 4.41 (s, 2H), 3.81 (d, $J = 1.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.0, 164.6, 147.6, 138.2, 135.6, 133.3, 132.7, 131.6, 131.2, 129.6, 127.9, 127.1, 124.0, 123.9, 122.1, 121.1, 119.8, 119.5, 109.9, 105.8, 56.0, 46.3. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{20}\text{O}_3\text{N}_2\text{Br}$, 463.0652, found, 463.0652.

2-(3-([1,1'-Biphenyl]-4-yl)-1-oxoisquinolin-2(1H)-yl)-N-(tert-butyl)acetamide (**6a**). It was synthesized according to procedure C on a 0.15 mmol scale to yield final compound **6a** (52 mg, 85%) as a white solid. mp: 194–196 °C. $R_f = 0.62$ (50% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 8.45 (d, $J = 8.0$ Hz, 1H), 7.69–7.62 (m, 5H), 7.57–7.46 (m, 6H), 7.39 (t, $J = 7.3$ Hz, 1H), 6.54 (s, 1H), 5.88 (s, 1H), 4.48 (s, 2H), 1.34 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 167.1, 163.6, 143.7, 142.2, 140.3, 136.7, 134.6, 132.9, 129.9, 129.1, 128.2, 127.9, 127.4, 127.3, 126.9, 126.1, 124.9, 108.4, 51.6, 50.6, 28.8. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{27}\text{O}_2\text{N}_2$, 411.2067, found, 411.2062.

(Z)-N-(tert-Butyl)-2-(1-((4'-methoxy-[1,1'-biphenyl]-4-yl)-methylene)-3-oxoisindolin-2-yl)acetamide (**6b**). It was synthesized according to procedure C on a 0.15 mmol scale to yield final compound **6b** (60 mg, 91%) as a light yellow oil. $R_f = 0.76$ (50% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.89 (dd, $J = 7.6, 0.9$ Hz, 1H), 7.78 (d, $J = 7.8$ Hz, 1H), 7.67–7.44 (m, 7H), 7.39 (d, $J = 8.0$ Hz, 2H), 7.00 (d, $J = 8.7$ Hz, 2H), 6.82 (s, 1H), 5.05 (s, 1H), 4.26 (s, 2H), 3.86 (s, 3H), 1.23 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.4, 166.1, 159.6, 140.2, 138.6, 135.2, 132.9, 132.7, 132.5, 130.2, 129.2, 127.8, 126.6, 123.7, 119.7, 114.5, 106.9, 55.5, 51.5, 46.4. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{O}_3\text{N}_2$, 441.2173, found, 441.2172.

Methyl(2-(1-benzylidene-3-oxoisindolin-2-yl)acetyl) glycinate ($Z:E = 26:74$) (**6d**). It was synthesized according to procedure C on a 0.5 mmol scale to yield carboxylic acid **6c**, which was suspended in methanol and cooled to 0 °C. Then, SOCl_2 was added dropwise and the mixture was further stirred for 4 h. After the reaction, the solvent was removed under reduced pressure and the crude product was extracted with water and DCM, the combined organic layer was dried over Na_2SO_4 , the solvent was removed, and the crude was purified to give final compound **3d** (92 mg, 53%). White solid. mp: 149–150 °C. $R_f = 0.16$ (50% EtOAc/petroleum ether). ^1H NMR (500 MHz, CDCl_3) δ 7.86 (t, $J = 7.3$ Hz, 3H), 7.77 (d, $J = 7.8$ Hz, 1H), 7.63 (t, $J = 7.6$ Hz, 1H), 7.51 (t, $J = 7.5$ Hz, 1H), 7.40–7.36 (m, 3H), 6.86 (s, 1H), 5.97 (t, $J = 5.2$ Hz, 1H), 4.28 (s, 2H), 3.90 (d, $J = 5.1$ Hz, 2H),

3.73 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 170.1, 169.3, 167.4, 138.4, 134.9, 134.4, 134.1, 132.4, 129.4, 128.5, 128.1, 123.8, 123.7, 119.8, 107.7, 52.5, 45.7, 41.3. (E) ^1H NMR (500 MHz, CDCl_3) δ 7.44 (dt, $J = 13.3, 7.6$ Hz, 5H), 7.36–7.30 (m, 4H), 6.64 (s, 1H), 6.63–6.60 (m, 1H), 4.61 (s, 2H), 4.06 (d, $J = 5.5$ Hz, 2H), 3.71 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.9, 168.0, 166.9, 135.8, 135.3, 134.7, 132.7, 129.7, 129.6, 128.8, 128.2, 127.7, 123.7, 123.5, 112.4, 52.5, 43.9, 41.2. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{O}_4\text{N}_2$, 351, 1345, found, 351, 1332.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.2c01905>.

Experimental procedure and ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra

for all compounds with the X-ray crystallographic data for **3e**, **3i**, **5a**, ^1H - ^{13}C HMBC NMR spectra for **3a** and **5a** (PDF)

Accession Codes

CCDC 2168278–2168280 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

CCDC 2168278, 2168279, and 2168280 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, U.K.; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Author

Alexander Dömling – Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands;
orcid.org/0000-0002-9923-8873; Email: a.s.domling@rug.nl

Authors

Xin Li – Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands

Qian Wang – Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands

Qiang Zheng – Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands

Katarzyna Kurpiewska – Faculty of Chemistry, Department of Crystal Chemistry and Crystal, Physics, Biocrystallography Group, Jagiellonian University, 30-387 Krakow, Poland

Justyna Kalinowska-Fluszczyk – Faculty of Chemistry, Department of Crystal Chemistry and Crystal, Physics, Biocrystallography Group, Jagiellonian University, 30-387 Krakow, Poland; orcid.org/0000-0001-7714-1651

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acs.joc.2c01905>

Author Contributions

§ X.L. and Q.W. contributed equally to this work.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank Marcel de Vries and W.H.C. Huibers (University of Groningen) for their help in HRMS analysis. X.L., Q.W., and Q.Z. acknowledge the China Scholarship Council for support.

REFERENCES

- (1) (a) Ruijter, E.; Scheffelaar, R.; Orru, R. V. Multicomponent reaction design in the quest for molecular complexity and diversity. *Angew. Chem., Int. Ed.* **2011**, *50*, 6234–6246. (b) Xu, Z.; De Moliner, F.; Cappelli, A. P.; Hulme, C. Ugi/Aldol Sequence: Expeditious Entry to Several Families of Densely Substituted Nitrogen Heterocycles. *Angew. Chem., Int. Ed.* **2012**, *51*, 8037–8040.
- (2) Kreye, O.; Türling, O.; Sehlinger, A.; Rackwitz, J.; Meier, M. A. Structurally diverse polyamides obtained from monomers derived via the Ugi multicomponent reaction. *Chem.-Eur. J.* **2012**, *18*, 5767–5776.
- (3) Brown, M. L.; Aaron, W.; Austin, R. J.; Chong, A.; Huang, T.; Jiang, B.; Kaizerman, J. A.; Lee, G.; Lucas, B. S.; McMinn, D. L.; et al. Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothed antagonist hit. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5206–5209.
- (4) Wang, Q.; Mgimpatsang, K. C.; Li, X.; Domling, A. Isoquinolone-4-Carboxylic Acids by Ammonia-Ugi-4CR and Copper-Catalyzed Domino Reaction. *J. Org. Chem.* **2021**, *86*, 9771–9780.
- (5) (a) Basso, A.; Banfi, L.; Riva, R. A marriage of convenience: combining the power of isocyanide-based multicomponent reactions with the versatility of (hetero) norbornene chemistry. *Eur. J. Org. Chem.* **2010**, *2010*, 1831–1841. (b) Ugi, I.; Werner, B.; Dömling, A. The Chemistry of Isocyanides, their MultiComponent Reactions and their Libraries. *Molecules*. **2003**, *8*, 53–66. (c) Quan, B.-X.; Shuai, H.; Xia, A.-J.; Hou, Y.; Zeng, R.; Liu, X.-L.; Lin, G.-F.; Qiao, J.-X.; Li, W.-P.; Wang, F.-L.; et al. An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. *Nat. Microbiol.* **2022**, *7*, 716–725. (d) Casak, S. J.; Pradhan, S.; Fashoyin-Aje, L. A.; Ren, Y.; Shen, Y. L.; Xu, Y.; Chow, E. C.; Xiong, Y.; Zirkelbach, J. F.; Liu, J. FDA Approval Summary: Ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation FDA Approval: Ivosidenib in IDH1-mutated CCA. *Clin. Cancer Res.* **2022**, *28*, OF1–OF5.
- (6) Kelly, M. G.; Kincaid, J.; Fang, Y.; He, J.; Cao, Y.; Kaub, C.; Gowlugari, S.; Wang, Z. Bicycloheteroaryl Compounds as p2x7 Modulators and Uses Thereof. US20070225324A1, 2007.
- (7) Troiano, V.; Scarbaci, K.; Ettari, R.; Micale, N.; Cerchia, C.; Pinto, A.; Schirmeister, T.; Novellino, E.; Grasso, S.; Lavecchia, A.; Zappalà, M. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. *Eur. J. Med. Chem.* **2014**, *83*, 1–14.
- (8) Gao, D. X.; Wang, Y. X.; Chen, S. J.; Yang, H. P. Benzazepine Derivative, Preparation Method, Pharmaceutical Composition and Use Thereof. WO2017190669A2017.
- (9) (a) Armoiry, X.; Aulagner, G.; Facon, T. Lenalidomide in the treatment of multiple myeloma: a review. *J. Clin. Pharm. Ther.* **2008**, *33*, 219–226. (b) Li, S.; Gill, N.; Lentzsch, S. Recent advances of IMiDs in cancer therapy. *Curr. Opin. Oncol.* **2010**, *22*, 579–585. (c) Kotla, V.; Goel, S.; Nischal, S.; Heuck, C.; Vivek, K.; Das, B.; Verma, A. Mechanism of action of lenalidomide in hematological malignancies. *J. Hematol. Oncol.* **2009**, *2*, 36. (d) Yang, B.; Yu, R.-L.; Chi, X.-h.; Lu, X.-c. Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS One* **2013**, *8*, No. e64354. (e) Bennett, C. L.; Angelotta, C.; Yarnold, P. R.; Evens, A. M.; Zonder, J. A.; Raisch, D. W.; Richardson, P. Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. *JAMA* **2006**, *296*, 2555–2560.
- (10) Ibrahim, T. M. Synthesis of biologically active 3-benzalphthalide derivatives. *Arch. Pharm. Res.* **1991**, *14*, 342–345.

(11) Wang, S.; Song, Y.; Liu, D. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. *Cancer Lett.* **2017**, *385*, 51–54.

(12) Jia, Y.; Yun, C.-H.; Park, E.; Ercan, D.; Manuia, M.; Juarez, J.; Xu, C.; Rhee, K.; Chen, T.; Zhang, H.; et al. Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors. *Nature* **2016**, *534*, 129–132.

(13) Ma, Z.; Xiang, Z.; Luo, T.; Lu, K.; Xu, Z.; Chen, J.; Yang, Z. Synthesis of functionalized quinolines via Ugi and Pd-catalyzed intramolecular arylation reactions. *J. Comb. Chem.* **2006**, *8*, 696–704.

(14) Wang, Q.; Tuinhof, J.; Mgimpatsang, K. C.; Kurpiewska, K.; Kalinowska-Tluscik, J.; Dömling, A. Copper-Catalyzed Modular Assembly of Polyheterocycles. *J. Org. Chem.* **2020**, *85*, 9915–9927.

(15) Nie, Q.; Fang, X.; Liu, C.; Zhang, G.; Fan, X.; Li, Y.; Li, Y. DNA-Compatible ortho-Phthalaldehyde (OPA)-Mediated 2-Substituted Isoindole Core Formation and Applications. *J. Org. Chem.* **2022**, *87*, 2551–2558.

(16) (a) Wang, F.; Liu, H.; Fu, H.; Jiang, Y.; Zhao, Y. An efficient one-pot copper-catalyzed approach to isoquinolin-1 (2H)-one derivatives. *Org. Lett.* **2009**, *11*, 2469–2472. (b) Li, L.; Wang, M.; Zhang, X.; Jiang, Y.; Ma, D. Assembly of substituted 3-methyleneisoindolin-1-ones via a CuI/L-proline-catalyzed domino reaction process of 2-bromobenzamides and terminal alkynes. *Org. Lett.* **2009**, *11*, 1309–1312. (c) Liu, C.-C.; Parthasarathy, K.; Cheng, C.-H. Synthesis of highly substituted isoquinolone derivatives by nickel-catalyzed annulation of 2-halobenzamides with alkynes. *Org. Lett.* **2010**, *12*, 3518–3521. (d) Kavala, V.; Wang, C.-C.; Barange, D. K.; Kuo, C.-W.; Lei, P.-M.; Yao, C.-F. Synthesis of isocoumarin derivatives via the copper-catalyzed tandem sequential cyclization of 2-halo-N-phenyl benzamides and acyclic 1, 3-diketones. *J. Org. Chem.* **2012**, *77*, 5022–5029. (e) Shi, Y.; Zhu, X.; Mao, H.; Hu, H.; Zhu, C.; Cheng, Y. Synthesis of Functionalized Isoquinolin-1 (2H)-ones by Copper-Catalyzed α -Arylation of Ketones with 2-Halobenzamides. *Chem.–Eur. J.* **2013**, *19*, 11553–11557. (f) GangadharaáChary, R.; VaraáPrasad, K.; ShivaáKumar, K. A simple access to N-(un)substituted isoquinolin-1 (2 H)-ones: unusual formation of regioisomeric isoquinolin-1 (4 H)-ones. *ChemComm.* **2014**, *50*, 6797–6800. (g) Huang, C.-Y.; Kavala, V.; Kuo, C.-W.; Konala, A.; Yang, T.-H.; Yao, C.-F. Synthesis of biologically active indenoisoquinoline derivatives via a one-pot copper (II)-catalyzed tandem reaction. *J. Org. Chem.* **2017**, *82*, 1961–1968. (h) Yu, X.; Chen, K.; Guo, S.; Shi, P.; Song, C.; Zhu, J. Direct access to cobaltacycles via C–H activation: N-Chloroamide-enabled room-temperature synthesis of heterocycles. *Org. Lett.* **2017**, *19*, 5348–5351.

(17) (a) Zheng, Q.; Kurpiewska, K.; Dömling, A. SNAr Isocyanide Diversification. *Eur. J. Org. Chem.* **2022**, *2022*, No. e202101023. (b) Lei, X.; Thomaidi, M.; Angeli, G. K.; Dömling, A.; Neochoritis, C. G. Fluorene-based multicomponent reactions. *Synlett.* **2022**, *33*, 155–160. (c) Sutanto, F.; Shaabani, S.; Oerlemans, R.; Eris, D.; Patil, P.; Hadian, M.; Wang, M.; Sharpe, M. E.; Groves, M. R.; Dömling, A. Combining High-Throughput Synthesis and High-Throughput Protein Crystallography for Accelerated Hit Identification. *Angew. Chem., Int. Ed.* **2021**, *60*, 18231–18239. (d) Wang, Q.; Mgimpatsang, K. C.; Konstantinidou, M.; Shishkina, S. V.; Dömling, A. 1,3,4-Oxadiazoles by Ugi-Tetrazole and Huisgen Reaction. *Org. Lett.* **2019**, *21*, 7320–7323. (e) Wang, Q.; Osipyan, A.; Konstantinidou, M.; Butera, R.; Mgimpatsang, K. C.; Shishkina, S. V.; Dömling, A. Pd-Catalyzed de Novo Assembly of Diversely Substituted Indole-Fused Polyheterocycles. *J. Org. Chem.* **2019**, *84*, 12148–12156.

(18) Patil, P.; Ahmadian-Moghaddam, M.; Dömling, A. Isocyanide 2.0. *Green Chem.* **2020**, *22*, 6902–6911.